Affordable Access

deepdyve-link
Publisher Website

Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?

Authors
  • Smith-Cohn, Matthew A1
  • Burley, Nicholas B2
  • Grossman, Stuart A3
  • 1 Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, USA.
  • 2 Department of Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD, USA.
  • 3 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Type
Published Article
Journal
Current neuropharmacology
Publication Date
Jan 01, 2022
Volume
20
Issue
7
Pages
1383–1399
Identifiers
DOI: 10.2174/1570159X20999220131163504
PMID: 35100958
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The blood-brain barrier inhibits the central nervous system penetration of 98% of small molecule drugs and virtually all biologic agents, which has limited progress in treating neurologic disease. Vasoactive peptides have been shown in animal studies to transiently disrupt the blood-brain barrier and regadenoson is currently being studied in humans to determine if it can improve drug delivery to the brain. However, many other vasoactive peptides could potentially be used for this purpose. We performed a review of the literature evaluating the physiologic effects of vasoactive peptides on the vasculature of the brain and systemic organs. To assess the likelihood that a vasoactive peptide might transiently disrupt the blood-brain barrier, we devised a four-tier classification system to organize the available evidence. We identified 32 vasoactive peptides with potential blood-brain barrier permeabilityaltering properties. To date, none of these are shown to open the blood-brain barrier in humans. Twelve vasoactive peptides increased blood-brain barrier permeability in rodents. The remaining 20 had favorable physiologic effects on blood vessels but lacked specific information on permeability changes to the blood-brain barrier. Vasoactive peptides remain an understudied class of drugs with the potential to increase drug delivery and improve treatment in patients with brain tumors and other neurologic diseases. Dozens of vasoactive peptides have yet to be formally evaluated for this important clinical effect. This narrative review summarizes the available data on vasoactive peptides, highlighting agents that deserve further in vitro and in vivo investigations. Copyright© Bentham Science Publishers; For any queries, please email at [email protected]

Report this publication

Statistics

Seen <100 times